- Home
- DXYZ vs XERS Comparison
DXYZ vs XERS Comparison
Compare DXYZ & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- XERS
- Stock Information
- Founded
- DXYZ N/A
- XERS 2005
- Country
- DXYZ
- XERS United States
- Employees
- DXYZ N/A
- XERS N/A
- Industry
- DXYZ
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- XERS Health Care
- Exchange
- DXYZ Nasdaq
- XERS Nasdaq
- Market Cap
- DXYZ 581.6M
- XERS 526.3M
- IPO Year
- DXYZ 2024
- XERS 2018
- Fundamental
- Price
- DXYZ $48.17
- XERS $3.75
- Analyst Decision
- DXYZ
- XERS Strong Buy
- Analyst Count
- DXYZ 0
- XERS 4
- Target Price
- DXYZ N/A
- XERS $5.15
- AVG Volume (30 Days)
- DXYZ N/A
- XERS 1.8M
- Earning Date
- DXYZ N/A
- XERS 03-05-2025
- Dividend Yield
- DXYZ N/A
- XERS N/A
- EPS Growth
- DXYZ N/A
- XERS N/A
- EPS
- DXYZ N/A
- XERS N/A
- Revenue
- DXYZ N/A
- XERS $187,361,000.00
- Revenue This Year
- DXYZ N/A
- XERS $25.11
- Revenue Next Year
- DXYZ N/A
- XERS $19.29
- P/E Ratio
- DXYZ N/A
- XERS N/A
- Revenue Growth
- DXYZ N/A
- XERS 22.72
- 52 Week Low
- DXYZ N/A
- XERS $1.69
- 52 Week High
- DXYZ N/A
- XERS $4.10
- Technical
- Relative Strength Index (RSI)
- DXYZ N/A
- XERS 57.32
- Support Level
- DXYZ N/A
- XERS $3.51
- Resistance Level
- DXYZ N/A
- XERS $4.10
- Average True Range (ATR)
- DXYZ 0.00
- XERS 0.17
- MACD
- DXYZ 0.00
- XERS 0.03
- Stochastic Oscillator
- DXYZ 0.00
- XERS 46.15
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.